Gene Therapy Companies Among Top M&A Targets In 2020
Novo Nordisk And Gilead Tipped To Spend
Executive SummaryZolgensma shows that a gene therapy can be a commercial hit - but there's still plenty to be wary of in this cutting-edge field.
You may also be interested in...
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.